Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.64 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.56 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.45 |
| ▸ | DAO | P14920 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13634219 | 0.93 | UCHL1 (0.59) | CA2AKR1C3ENPP2PTGS2PTGS1 | |
| SCHEMBL10314958 | 0.88 | CA2 (0.52) | CA2AKR1C3PTGS2PTGS1UCHL1 | |
| SCHEMBL13231429 | 0.82 | ENPP2 (0.54) | CA2ENPP2PTGS2HPGDALDH1A1 | |
| SCHEMBL678812 | 0.82 | CA2 (0.67) | CA2UCHL1KMT2AL3MBTL1HPGD | |
| SCHEMBL8974175 | 0.82 | PTGS2 (0.47) | CA2AKR1C3PTGS2PTGS1UCHL1 | |
| SCHEMBL4112642 | 0.82 | RAB9A (0.61) | CA2AKR1C3PTGS2KMT2ATP53 | |
| SCHEMBL8658311 | 0.82 | PTGS2 (0.74) | PTGS2PTGS1 | |
| SCHEMBL23554860 | 0.81 | CA2 (0.59) | CA2AKR1C3UCHL1KMT2AL3MBTL1 | |
| SCHEMBL6793165 | 0.81 | CA2 (0.67) | CA2ENPP2PTGS2KMT2AL3MBTL1 | |
| SCHEMBL10204298 | 0.81 | CA2 (0.59) | CA2AKR1C3UCHL1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 377 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148537-B2 | Substituted acetophenones useful as PDE4 inhibitors | LEO PHARMA A/S (DK) | 2012-04-03 | — | — | US | claimed |
| EP-2125736-B1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | LEO PHARMA AS (DK) | 2011-03-30 | — | — | EP | claimed |
| US-20100035908-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | LEO PHARMA (DK) | 2010-02-11 | — | — | US | claimed |
| CN-101611005-A | Be used as the acetophenones of the replacement of PDE4 inhibitor | LEO PHARMA AS (DK) | 2009-12-23 | — | — | CN | claimed |
| EP-2125736-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | Leo Pharma A/S (DK) | 2009-12-02 | — | — | EP | claimed |
| EP-1299354-B1 | FACTOR VIIA INHIBITORY (THIO)UREA DERIVATIVES, THEIR PREPARATION AND THEIR USE | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-07-22 | — | — | EP | claimed |
| WO-2008077404-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | LEO PHARMA A/S (DK) | 2008-07-03 | — | — | WO | claimed |
| US-12043613-B2 | Inhibitors of SARM1 | DISARM THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| WO-2024139260-A1 | ALLICIN DERIVATIVES, PREPARATION METHOD THEREFOR, AND USES THEREOF | 成都新朝阳作物科学股份有限公司 | 2024-07-04 | — | — | WO | disclosed |
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| WO-2023244963-A2 | BICYCLONONYNE REAGENTS FOR CELL IMAGING | THE GENERAL HOSPITAL CORPORATION (US) | 2023-12-21 | — | — | WO | disclosed |
| WO-2023225001-A1 | NAPHTHYRIDINE BASED ENPP1 MODULATORS AND USES THEREOF | Vir Biotechnology, Inc. (US) | 2023-11-23 | — | — | WO | disclosed |
| CN-116947720-A | Allicin derivative and preparation method and application thereof | 成都新朝阳作物科学股份有限公司 | 2023-10-27 | — | — | CN | disclosed |
| EP-1162194-A1 | Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use | Aventis Pharma Deutschland GmbH (DE) | 2001-12-12 | — | — | EP | disclosed |
| WO-2001007409-A1 | CARBAZOLE DERIVATIVES AND THEIR USE AS NEUROPEPTIDE Y5 RECEPTOR LIGANDS | ASTRAZENECA UK LIMITED (GB) | 2001-02-01 | — | — | WO | disclosed |
| CN-1263612-A | Chemically amplified resist composition | CLARIANT INT LTD (CH) | 2000-08-16 | — | — | CN | disclosed |
| CN-1263611-A | Method for forming pattern | CLARIANT INT LTD (CH) | 2000-08-16 | — | — | CN | disclosed |
| EP-0470103-B1 | PROCESS FOR THE PRODUCTION OF ALKANE SULPHONYL BENZOIC ACIDS | HOECHST AG (DE) | 1994-07-27 | — | — | EP | disclosed |
| EP-0470103-A1 | PROCESS FOR THE PRODUCTION OF ALKANE SULPHONYL BENZOIC ACIDS. | HOECHST AG (DE) | 1992-02-12 | — | — | EP | disclosed |
| WO-1990013537-A1 | PROCESS FOR THE PRODUCTION OF ALKANE SULPHONYL BENZOIC ACIDS | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035908-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE3B | CA2 364/4885AKR1C3 45/4885ENPP2 351/4885 |
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | CA2 4080/4885AKR1C3 899/4885ENPP2 4062/4885 |
| US-12043613-B2 | Inhibitors of SARM1 | SARM1, SMN1; SMN2, SARNP | CA2 4714/4885AKR1C3 4247/4885ENPP2 2779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.